|Bid||61.91 x 1000|
|Ask||66.00 x 500|
|Day's Range||64.44 - 66.07|
|52 Week Range||42.62 - 86.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.36|
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.
The US Patent Office Patent Trial and Appeal Board recently ruled to uphold the validity of WaveForm Technologies Inc. patents in the emerging field of continuous glucose monitoring SALEM, N.H. and WILSONVILLE, ...
The San Diego-based company said it had a loss of 11 cents per share. Earnings, adjusted for pretax expenses, were 10 cents per share. The results beat Wall Street expectations. The average estimate of ...
DexCom, Inc. today reported its financial results as of and for the quarter and fiscal year ended December 31, 2017.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / DexCom, Inc. (NASDAQ: DXCM ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern Time. ...
DexCom (NASDAQ: DXCM ) will be releasing its next round of earnings Tuesday. For all of the relevant information, here is your guide for today's Q4 earnings announcement. Earnings and Revenue Based on ...
The bulls that were plowing into Fitbit Inc (NYSE:FIT) headed into Thursday’s post-close earnings report are likely regretting that decision now. After gaining 5% during regular trading hours, Fitbit stock is now tanking the tune of 13% in pre-market action when disappointing results were underscored by even more disappointing guidance. No. If nothing else, Fitbit is a powerful brand name that will always be able to leveraged somehow.
DexCom Inc (NASDAQ:DXCM), a medical equipment company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs ofRead More...
Fitbit shares dropped 13% in after-hours trading on Monday after the company missed on earnings and revenue for its fiscal fourth quarter.
The Soros Fund Management opened up smallish positions in the mid-cap biotechs DexCom and AnaptysBio in the most recent quarter.
Diverse product portfolio and strong veterinary business prospects to drive Patterson Companies (PDCO) in Q3. However, sluggishness in the Dental-Supply segment is a woe.
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DexCom, Inc. (DXCM), has today released the findings of the HypoDE study, a multi-centre, randomised controlled trial (RCT) which was discussed on Friday 15th February at ATTD. The study found that the use of Dexcom continuous glucose monitoring (CGM) reduces the frequency and severity of hypoglycaemic events among high-risk individuals with type 1 diabetes treated with multiple daily injections (MDI) of insulin. Hypoglycaemia remains a key limiting factor in achieving optimal glycaemic control in people with type 1 diabetes, and the vast majority of these individuals are treated with MDI globally.
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like DexCom Inc (NASDAQ:DXCM), with a market cap of US$4.98B, are often out of the spotlight.Read More...
In fiscal 4Q17, Abbott Laboratories(ABT) invested ~6.9% of its total sales in R&D (research and development). In fiscal 2018, the company plans to invest ~7.5% of its total sales. Abbott Laboratories launched more than 20 new products in fiscal 2017. Abbott Laboratories now has an attractive product pipeline, boosted by the recent acquisitions—especially its acquisition of St. Jude Medical.
NEW YORK, Feb. 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Valero ...
DexCom, Inc. today announced that it plans to release its fourth quarter and full year 2017 financial results after market close on Tuesday, February 27, 2018. Management will hold a conference call to review the company's fourth quarter and full year 2017 performance starting at 4:30 p.m.
Johnson & Johnson (JNJ) released its 4Q17 and fiscal 2017 results on January 23, 2018. The company reported sales growth across its three business segments: Pharmaceuticals, Medical Devices, and Consumer Businesses. The company’s medical device business contributed ~35% to J&J’s total sales in fiscal 4Q17.
UnitedHealthcare, the market leader in Medicare benefit plans1, and DexCom, Inc., the leader in continuous glucose monitoring for diabetes management, today announced an individualized glucose management pilot program driven by wearable technology to help people with Type 2 diabetes manage their condition in real time.